SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 91.78 |
Enterprise Value ($M) | 60.73 |
Book Value ($M) | 32.01 |
Book Value / Share | 2.10 |
Price / Book | 2.87 |
NCAV ($M) | 31.96 |
NCAV / Share | 2.10 |
Price / NCAV | 2.87 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -0.33 |
Return on Assets (ROA) | -0.90 |
Return on Equity (ROE) | -1.06 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 15.31 |
Current Ratio | 15.31 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 35.51 |
Assets | 35.55 |
Liabilities | 3.54 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 0.00 |
Operating Income | 0.00 |
Net Income | 0.00 |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | 0.00 |
Cash from Investing | 0.00 |
Cash from Financing | 0.00 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13G/A | Vanguard Group Inc | 5.55 | 0.00 | |
13G/A | Greenlight Capital Inc | 8.80 | -0.39 | |
13G/A | Hirschman Orin | 8.10 | 68.17 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
File Date | Form | SEC Filings |
---|---|---|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
7,828 | 45,210 | 17.31 | |
5,717 | 36,549 | 15.64 | |
7,571 | 70,688 | 10.71 | |
20,730 | 78,062 | 26.56 | |
(click for more detail) |
Financial data and stock pages provided by
Fintel.io